These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9592806)

  • 21. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.
    Malfroid M; Hens L; Roosen P; Dom R
    Acta Psychiatr Belg; 1978; 78(1):147-54. PubMed ID: 347877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
    Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
    Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl.
    Palkama VJ; Neuvonen PJ; Olkkola KT
    Br J Anaesth; 1998 Oct; 81(4):598-600. PubMed ID: 9924238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
    Yasui-Furukori N; Saito M; Furukori H; Inoue Y; Someya T; Kaneko S; Tateishi T
    Ther Drug Monit; 2004 Jun; 26(3):336-41. PubMed ID: 15167638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats.
    Watanabe M; Tateishi T; Asoh M; Nakura H; Tanaka M; Kumai T; Kobayashi S
    Fundam Clin Pharmacol; 1999; 13(3):337-42. PubMed ID: 10392310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
    Fang J; Baker GB; Silverstone PH; Coutts RT
    Cell Mol Neurobiol; 1997 Apr; 17(2):227-33. PubMed ID: 9140699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone.
    Masui T; Kusumi I; Takahashi Y; Koyama T
    Ther Drug Monit; 2006 Feb; 28(1):73-5. PubMed ID: 16418697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Kaneko S; Inoue Y; Shibata M; Ikeda K
    Ther Drug Monit; 1997 Apr; 19(2):165-8. PubMed ID: 9108644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactin response to bromperidol treatment in schizophrenic patients.
    Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y
    Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.
    Araki K; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Inoue Y; Tateishi T; Otani K
    Eur J Clin Pharmacol; 2004 Aug; 60(6):427-30. PubMed ID: 15232663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.
    Yasui-Furukori N; Furukori H; Saito M; Inoue Y; Kaneko S; Tateishi T
    Ther Drug Monit; 2003 Dec; 25(6):709-14. PubMed ID: 14639057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open study with bromperidol in hospitalized chronic schizophrenic patients.
    Hermans W
    Acta Psychiatr Belg; 1978; 78(1):89-95. PubMed ID: 347883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
    Yasui-Furukori N; Kondo T; Ishida M; Furukori H; Suzuki A; Kaneko S; Inoue M; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):53-7. PubMed ID: 11853119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.